MedinCell & Teva: Olanzapine LAI Phase 3 Positive, Uzedy Real-World Data
Medincell‘s long-acting injectable technology, BEPO®, has achieved commercial success with its first product, UZEDY® (risperidone LAI), for treating schizophrenia...
Medincell‘s long-acting injectable technology, BEPO®, has achieved commercial success with its first product, UZEDY® (risperidone LAI), for treating schizophrenia...
CinFina Pharma, a CinRx portfolio company focused on obesity treatments, has released promising interim data from a Phase 1...
Hedonia, a mobile mental health solutions provider, has released promising findings from a recent economic model. The study, conducted...
Fulgent Genetics, a technology-driven company specializing in laboratory services and therapeutic development, secured a five-year contract with the U.S....
Sunbird Bio, a biotechnology company focused on neurological disorders and early-stage cancer diagnostics, has unveiled promising data regarding its...
Scholar Rock, a late-stage biopharmaceutical company specializing in treatments for serious diseases like spinal muscular atrophy (SMA), cardiometabolic disorders,...
Bristol Myers Squibb recently unveiled positive topline results from two Phase 3 open-label trials, EMERGENT-4 and EMERGENT-5. These trials...
Mirum Pharmaceuticals will participate in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting from...
ChromaDex Corp. reported strong third-quarter 2024 financial results, marked by record revenue, net income, and adjusted EBITDA. The company...
KORU Medical Systems presented data at the 2024 PODD Conference showcasing nurse preference for the KORU FreedomEdge® Infusion System...